Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin renal oxygenation in non-diabetic subjects
NCT03093103Phase 2Completed
- Sponsor
- Lausanne University Hospital
- Start
- Mar 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic kidney disease (CKD) comparing Empagliflozin 10mg with Placebo (2 arms). Primary endpoint: Renal tissue oxygenation at 4 weeks. Started Mar 2017; status: completed.
02
Drugs
empagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT03093103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03093103.